Results 251 to 260 of about 69,283 (286)
Some of the next articles are maybe not open access.
FR226807: a potent and selective phosphodiesterase type 5 inhibitor
European Journal of Pharmacology, 2001We describe the pharmacological characteristics of a novel phosphodiesterase type 5 inhibitor FR226807, N-(3,4-dimethoxybenzyl)-2-[[(1R)-2-hydroxy-1-methylethyl]amino]-5-nitrobenzamide. FR226807 inhibited phosphodiesterase type 5 isolated from human platelets with an IC(50) value of 1.1 nM. FR226807 also inhibited phosphodiesterase type 6 with an IC(50)
N, Hosogai +12 more
openaire +2 more sources
Chronic dosing of phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2008Ten years ago, the introduction of sildenafil citrate for the treatment of erectile dysfunction fundamentally changed the field of sexual medicine. The sexual indications, along with the pharmacologic characteristics of this drug, led to its approval for on-demand use.
openaire +1 more source
Effects of phosphodiesterase type 5 inhibitors on Raynaud’s phenomenon
Rheumatology International, 2014Raynaud's phenomenon (RP) is commonly observed in fingers and toes of patients with connective tissue diseases (CTDs). However, existing vasodilators have very limited efficacy. In this study, phosphodiesterase type 5 inhibitors (PDE-5Is) were administered to evaluate efficacy on RP.
Yasuyuki, Kamata, Seiji, Minota
openaire +2 more sources
Thromboangiitis obliterans successfully treated with phosphodiesterase type 5 inhibitors
Vascular, 2013Thromboangiitis obliterans, or Buerger’s disease, is a non-atherosclerotic, segmental, inflammatory disease affecting the small- and medium-sized vessels of the distal extremities. Other than discontinuation of tobacco, there is no standard-of-care treatment.
Aryeh M, Abeles +3 more
openaire +2 more sources
Optimizing response to phosphodiesterase type 5 inhibitors
Current Sexual Health Reports, 2007Although using phosphodiesterase type 5 inhibitors to treat erectile dysfunction has been highly effective in clinical trials, many men do not achieve their desired goals and stop using the medication after a few attempts. The notion of optimizing response to pharmacologic interventions is relatively new to clinicians.
openaire +1 more source
[Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Revue medicale de Bruxelles, 2003Erectile dysfunction affects 150 millions of men and its prevalence increases with age. The improvement of life expectancy will increase the worldwide prevalence to 300 million in 2025. Oral treatments are nowadays the first line therapy for the vast majority of people as they have a good reliability and tolerance and restore more spontaneity.
T, Roumeguère +2 more
openaire +1 more source
Phosphodiesterase Type 5 Inhibitors: State of the Therapeutic Class
Urologic Clinics of North America, 2007With three effective and safe phosphodiesterase type 5 (PDE5) inhibitors, the clinician now has multiple choices in the treatment of patients who have erectile dysfunction of all severities and etiologies. Based on pharmacokinetics, pharmacodynamics, efficacy, and safety, each of these agents can be used.
openaire +2 more sources
[Novel indications for phosphodiesterase type 5 inhibitors].
Medizinische Klinik (Munich, Germany : 1983), 2007Phosphodiesterase type 5 (PDE5) induces the breakdown of cyclic guanosine monophosphate (cGMP) in smooth muscle cells. Hence, PDE5 inhibitors promote vasodilative effects by enhancing intracellular cGMP levels. Three PDE5 inhibitors, sildenafil, vardenafil, and tadalafil, have been approved for the treatment of "erectile dysfunction" (ED).
Stephan, Rosenkranz +2 more
openaire +1 more source
Phosphodiesterase Type-5 Inhibitors: A Critical Comparative Analysis
EAU Update Series, 2004Abstract All three PDE5 inhibitors are targeting the same site of action e.g. PDE5 and this is why a quite similar efficacy and safety profile could be expected and was finally proven in many controlled studies. The efficacy as assessed by the endpoint successful intercourse with maintenance of erection (SEP3) ranges between 65 and 75% in broad ...
openaire +1 more source